Alba Therapeutics Appoints Wendy Perrow Chief Executive Officer
BALTIMORE, Nov. 5, 2013 /PRNewswire/– Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO). Her responsibilities include managing the Company’s business, clinical, financial, licensing, and corporate development efforts. Ms. Perrow previously served as President and COO and she has been a member of Alba’s executive management team since 2008.
Under her leadership, Alba Therapeutics established a collaborative funding agreement on February 9, 2011 with Cephalon Pharmaceuticals (now Teva Pharmaceuticals) and has taken a leading role in advancing multiple clinical studies in Celiac Disease. The company has conducted seven clinical trials in subjects with Celiac Disease and is currently conducting a large Phase IIb trial with the lead compound Larazotide Acetate.
“Ms. Perrow brings a wealth of global experience and leadership with a proven track record of success in both biotech and pharmaceutical companies,” said Bruce Peacock Co-Chairman of Alba. “Wendy is a key member of our leadership team, driving deal making as well as clinical and financial strategy and her experience in leading successful research and development and commercial infrastructures has been invaluable to Alba.”
Prior to joining Alba, Ms. Perrow held senior executive marketing positions with private and public pharmaceutical companies. From 2004 to 2007, she was Vice President of Marketing for Sigma-Tau Pharmaceuticals, Inc., a company focused on creating novel therapies for the unmet needs of patients with rare diseases. From 1989 to 2003, Ms. Perrow was at Merck and Co., Inc. in Global and U.S. marketing for Anti-Hypertensives, Vaccines, Cholesterol, and GI. At Merck, she held positions in marketing promotion, international business research analysis, training, and sales. Ms. Perrow began her career in a division of Johnson & Johnson. A skilled marketer and business leader, she has led U.S. and Global initiatives for leading products that have significantly increased brand awareness and has launched medicines for unmet medical needs.
“Throughout her career, Ms. Perrow has demonstrated a true passion and commitment to bring new scientific advances and medications to help improve the standard of care for patients who have rare and serious conditions around the globe,” said Matt Zuga Co-Chairman of Alba. “With her broad experience and proven leadership across research, development, and commercialization, we have been able to accelerate Alba’s mission to create medicines for patients with Celiac Disease. Her breadth of experience in building successful companies and establishing strong collaborations is a tremendous asset to Alba Therapeutics as we continue to establish our leadership position in the Celiac Disease field.”
Ms. Perrow holds a bachelor’s degree from Eastern Illinois University and a Masters of Business Administration degree in finance and marketing from Duke University – The Fuqua School of Business.
Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland.
SOURCE Alba Therapeutics Corporation